NASDAQ: CADL - Candel Therapeutics, Inc.

छह महीने के लिए लाभप्रदता: +41.92%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Candel Therapeutics, Inc.

उन्नत शेड्यूल सरल ग्राफ
Financial Markets by TradingView

कंपनी के बारे में Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

अधिक जानकारी
It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
तुलना सूची में जोड़ें
घड़ी सूची में जोड़ें
पोर्टफोलियो में जोड़ें
मूल्य सूचना जोड़ें

IPO date 2021-07-27
ISIN US1374041093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.candeltx.com
Цена ао 1.49
प्रति दिन मूल्य परिवर्तन: -3.27% (9.17)
प्रति सप्ताह मूल्य परिवर्तन: +1.37% (8.75)
प्रति माह मूल्य परिवर्तन: +79.19% (4.95)
3 महीने में कीमत में बदलाव: +23.02% (7.21)
छह महीने में कीमत में बदलाव: +41.92% (6.25)
प्रति वर्ष मूल्य परिवर्तन: +503.4% (1.47)
3 वर्षों में मूल्य परिवर्तन: +29.11% (6.87)
5 वर्षों में मूल्य परिवर्तन: 0% (8.87)
10 वर्षों में मूल्य परिवर्तन: 0% (8.87)
वर्ष की शुरुआत से मूल्य परिवर्तन: +122.31% (3.99)
सभी पैरामीटर

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 1064.07 1
P/BV 2.59 6
P/E 0 0
EV/EBITDA -0.5468 0
कुल: 3.5

क्षमता

नाम अर्थ श्रेणी
ROA, % -90.98 0
ROE, % -297.68 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.5859 10
कुल: 9.8

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % -75.2 0
लाभप्रदता Ebitda, % 392.51 10
लाभप्रदता EPS, % 205.63 10
कुल: 8
अधिक जानकारी

संस्थानों आयतन शेयर करना, %
Northpond Ventures, Llc 1935215 6.59
Sands Capital Ventures, LLC 811737 2.77
Vanguard Group Inc 425749 1.45
FMR, LLC 298384 1.02
Geode Capital Management, LLC 139253 0.47
Bridgeway Capital Management, Inc. 132595 0.45
Baystate Wealth Management LLC 76910 0.26
Blackrock Inc. 49285 0.17
OneDigital Investment Advisors LLC 29783 0.1
State Street Corporation 27600 0.09

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
iShares Micro-Cap ETF 0.03787 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01119 38.04 0.6026
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares UltraPro Russell2000 0.00323 89.82 1.47873
ProShares Hedge Replication ETF 0.00093 5.92 1.47892
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 ETF 0 17.16 1.48801



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (57 साल)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (47 साल)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (64 वर्ष)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (56 साल)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (40 साल)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (64 वर्ष)

पता: United States, Needham. MA, 117 Kendrick Street - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.candeltx.com